“Deucravacitinib, an oral, selective tyrosine kinase 2 inhibitor, versus placebo and apremilast in moderate to severe plaque psoriasis: analysis of body surface area involvement in the phase 3 POETYK PSO-1 and PSO-2 trials” (2022) SKIN The Journal of Cutaneous Medicine, 6(6), p. s45. doi:10.25251/skin.6.supp.45.